Zimmer Biomet Stock (US98956P1021): Q3 2025 Earnings Beat Expectations with 5.2% Revenue Growth

Zimmer Biomet reported third-quarter 2025 results on October 31, 2025, surpassing revenue forecasts with $2.06 billion, up 5.2% year-over-year. Adjusted EPS of $2.51 exceeded consensus estimates, according to the company's official press release.

Zimmer Biomet reported third-quarter 2025 results on October 31, 2025, surpassing revenue forecasts with $2.06 billion, up 5.2% year-over-year. Adjusted EPS of $2.51 exceeded consensus estimates, according to the company press release dated 10/31/2025.

As of: 10/31/2025

By the AD HOC NEWS Editorial Team – Equity Coverage.

At a Glance

• Name: Zimmer Biomet Holdings, Inc.
• ISIN: US98956P1021
• Sector/Industry: Healthcare / Medical Devices
• Headquarters/Country: Warsaw, Indiana / United States
• Primary Exchange: NYSE
• Trading Currency: USD
• CEO: Ivan T. Rakitin (since May 2024)
• Last Quarterly Results: Q3 2025 (published 10/31/2025)

How Zimmer Biomet Makes Money: The Core Business Model

Zimmer Biomet operates as a global leader in musculoskeletal healthcare technology, focusing on orthopedic implants, dental solutions, and related surgical technologies. The company generates revenue primarily through the sale of hip and knee reconstruction products, representing the largest segment, according to the 10-K filing for fiscal year 2024 dated 02/21/2025.

Additional revenue streams include extremities and trauma products, sports medicine, biologics, and spine solutions. Dental and bone cement products contribute to diversified income. The business model relies on innovation in implant design, robotic-assisted surgery systems, and patient-specific instrumentation to maintain market position in elective procedures.

Geographically, the United States accounts for over 50% of net sales, with international markets providing growth opportunities through established distribution networks and regulatory approvals. Manufacturing facilities in the US, Europe, and Asia support global supply chains.

Zimmer Biomet's Key Revenue and Product Drivers

In Q3 2025, net sales reached $2.06 billion, a 5.2% increase from $1.96 billion in Q3 2024, driven by 4.8% organic growth, according to the company press release dated 10/31/2025. The knees category grew 6.5% organically, while hips increased 3.9%.

Adjusted earnings per share came in at $2.51, above the consensus estimate of $2.35. The company reaffirmed full-year 2025 guidance for organic sales growth of 4.0-4.5% and adjusted EPS of $8.15-$8.30, as stated in the same press release.

Key product drivers include the ROSA Robotics platform, which saw strong adoption in knee procedures, and the Persona IQ smart knee implant, launched commercially in select markets during 2025.

Industry Trends and Competitive Landscape

The global orthopedic devices market is projected to reach $65.2 billion by 2027, growing at a CAGR of 5.1% from 2022, according to MarketsandMarkets report dated 2022. Aging populations and rising demand for joint replacement surgeries fuel expansion.

Competitors in hip and knee reconstruction include Stryker Corp. (NYSE: SYK), with leading market share in enabling technologies, and DePuy Synthes (a Johnson & Johnson unit), verified through their respective 10-K filings. Smith & Nephew plc competes in robotics and sports medicine.

Trends toward robotic-assisted surgery and value-based care models pressure device pricing but reward innovation in outcomes data and procedure efficiency.

Why Zimmer Biomet Matters to US Investors

Zimmer Biomet trades on the NYSE under ticker ZBH in USD, providing direct exposure to the US medical device sector for American investors. The company files regular reports with the SEC, including the recent 10-Q for Q3 2025.

With headquarters in Indiana and majority US revenue, Zimmer Biomet benefits from domestic Medicare reimbursement policies for orthopedic procedures. Inclusion in the S&P 500 index offers liquidity and benchmark relevance.

The stock traded at $107.45 on the NYSE on 10/31/2025 at 4:00 PM ET, according to NYSE.com, 10/31/2025, 4:00 PM ET.

Which Investor Profile Fits Zimmer Biomet – and Which Does Not?

Investors focused on defensive healthcare sectors with steady demand from demographic trends may find alignment with Zimmer Biomet's elective procedure exposure. Those seeking exposure to medtech innovation, particularly robotics, could note the company's investments.

Profiles prioritizing high dividend yields or rapid growth stocks may look elsewhere, given the mature orthopedic market dynamics and pricing pressures. Volatility tied to procedure volumes suits those comfortable with healthcare cyclicality.

Risks and Open Questions for Zimmer Biomet

Supply chain disruptions remain a concern, as highlighted in the Q3 2025 earnings call, with potential impacts from raw material shortages affecting implant production. Regulatory scrutiny on medical devices continues through FDA pathways.

Reimbursement changes under US healthcare programs could pressure margins. Competition in robotics intensifies, requiring sustained R&D investment.

Key Events and Outlook for Investors

Zimmer Biomet will report Q4 2025 results on February 6, 2026, pre-market, followed by a conference call at 8:30 AM ET, per the Q3 press release dated 10/31/2025.

What to Watch Next

• 02/06/2026: Q4 2025 Earnings Release & Conference Call
• Q1 2026: ROSA Robotics Adoption Metrics

Conclusion

Zimmer Biomet's Q3 2025 results demonstrated resilient growth amid procedure recovery, with knees and robotics as standout performers. The reaffirmed guidance signals management confidence in full-year targets. US investors continue monitoring volume trends and innovation pipeline for sustained performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.